The FDA approves nipocalimab (Imaavy; nipocalimab-aahu) as the first treatment for warm autoimmune hemolytic anemia (wAIHA), a condition in which the immune system targets red blood cells. The approval makes nipocalimab the initial approved therapy for the most common form of autoimmune hemolytic anemia.
Nipocalimab is an immunoselective neonatal Fc receptor (FcRn) blocker. By blocking FcRn, it reduces levels of pathogenic IgG autoantibodies that drive red blood cell destruction. While reducing those harmful antibodies, the drug is described as designed to preserve aspects of normal immune function, including B-cell activity.
Media coverage aligns on the core points: the FDA approval, the drug name and target mechanism, and the intended use in wAIHA. One outlet focuses more on the “first-ever” and “landmark” framing of the approval, while the other emphasizes that the therapy is the first approved option for this disease subtype.
